^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EBF1-PDGFRB fusion

    i
    Other names: PDGFRB, Platelet Derived Growth Factor Receptor Beta, Platelet-Derived Growth Factor Receptor, Beta Polypeptide, Beta-Type Platelet-Derived Growth Factor Receptor, Platelet-Derived Growth Factor Receptor Beta, Platelet-Derived Growth Factor Receptor 1, CD140 Antigen-Like Family Member B, PDGF-R-Beta, PDGFR-Beta, PDGFR-1, PDGFR1,Beta Platelet-Derived Growth Factor Receptor, Activated Tyrosine Kinase PDGFRB, CD140b Antigen, NDEL1-PDGFRB , CD140B, IBGC4, JTK12, PENTT, IMF1 , KOGS, EBF1, EBF Transcr
    Entrez ID:
    5159; 1879
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    6ms
    Frontline Combination of 3rd Generation TKI Olverembatinib and Blinatumomab for Ph+/Ph-like ALL Patients (ASH 2023)
    Background The combination of dasatinib and blinatumomab represented a chemotherapy-free treatment approach, which had been employed in the management of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). A recent study demonstrated that combination therapy of ponatinib with blinatumomab may achieve better efficacy, with a complete molecular response (CMR) rate of 87%...However, further clinical trials are needed to definitively establish the efficacy of this treatment approach and validate the potential benefits. This research was supported by the National Natural Science Foundation of China(NFSC82170163, 81970147), Clinical Study of Nanfang Hospital(LC2016ZD009/2019CR012).
    Clinical
    |
    PDGFRB (Platelet Derived Growth Factor Receptor Beta) • ETV6 (ETS Variant Transcription Factor 6) • EBF1 (EBF Transcription Factor 1)
    |
    EBF1-PDGFRB fusion • PDGFRB fusion
    |
    dasatinib • Iclusig (ponatinib) • Blincyto (blinatumomab) • Nailike (olverembatinib)
    1year
    Acute lymphoblastic leukemia with EBF1-PDGFRB fusion gene: two cases report and literature review (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    No abstract available
    Review • Journal
    |
    PDGFRB (Platelet Derived Growth Factor Receptor Beta) • EBF1 (EBF Transcription Factor 1)
    |
    EBF1-PDGFRB fusion • PDGFRB fusion
    over3years
    Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion. (PubMed, Ann Hematol)
    No abstract available
    Journal
    |
    PDGFRB (Platelet Derived Growth Factor Receptor Beta) • EBF1 (EBF Transcription Factor 1)
    |
    EBF1-PDGFRB fusion
    |
    imatinib